Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-positive Anaplastic T Large Cell Lymphoma Treated With Crizotinib

Rare Tumors - Italy
doi 10.4081/rt.2016.6266
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Enteropathy-Associated Anaplastic Large T Cell Lymphoma ALK-positive (EA-ALCL-ALK+): Variant of T Cell Lymphoma With Possible Two-Hit Pathogenesis

Journal of Hematopathology
Forensic MedicinePathologyHematologyHistology
2013English

Leukemic Phase of ALK-positive Anaplastic Large Cell Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2013English

ALK-negative Anaplastic Large Cell Lymphoma

2020English

ALK-positive Anaplastic Large Cell Lymphoma With Soft Tissue Involvement in a Young Woman

OncoTargets and Therapy
OncologyPharmacology
2016English

Intravascular ALK-Positive Anaplastic Large-Cell Lymphoma Mimicking Inflammatory Breast Carcinoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Prognostic Significance of NPM-ALK Fusion Transcript Overexpression in ALK-positive Anaplastic Large-Cell Lymphoma

Modern Pathology
Forensic MedicinePathology
2007English

48. Mediastinal ALK-positive Anaplastic Large Cell Lymphoma in a 12-Year Old Male

Pathology
Forensic MedicinePathology
2020English

Primary Cutaneous Anaplastic Large Cell Lymphoma

Journal of Cutaneous Pathology
DermatologyForensic MedicinePathologyHistology
2017English

Alk Expression Plays Different Roles in Anaplastic Large-Cell Lymphomas and Outcome of Crizotinib Use in Relapsed/Refractory Alk+ Patients in a Chinese Population

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy